ScienceMachine, a London-based AI startup, has secured $3.5 million in pre-seed funding to accelerate the adoption of autonomous artificial intelligence in biotech research. The company’s flagship product, an AI agent named Sam, acts as a 24/7 virtual bioinformatician, automating the entire data analysis pipeline for biotech and pharmaceutical companies. By leveraging Sam, research teams can process complex biological data more efficiently, overcoming the bottleneck of limited data science expertise and enabling faster scientific discovery.
The core innovation behind ScienceMachine is its ability to fully automate internal workflows, from data cleaning to exploratory analysis and visualization. Sam integrates seamlessly with existing databases and lab systems, continuously analyzing experimental data to uncover patterns, insights, and potential breakthroughs—without the need for manual intervention. This approach delivers results that would typically require an entire team of data scientists, significantly reducing both the time and cost associated with biotech research. Early adopters report that ScienceMachine’s solution produces high-quality results in a third of the time and at a fraction of the cost compared to traditional methods.
The recent funding round, led by Revent and Nucleus Capital, will support further product development and expansion, particularly in sales and pharma partnerships. ScienceMachine, founded by Lorenzo Sani and Benjamin Tenmann, has already attracted multiple biotech clients and is experiencing rapid growth driven by inbound demand. The company aims to extend its reach from startups to larger enterprises, where scalable and flexible data automation is increasingly vital. With its pioneering technology, ScienceMachine is poised to transform how life sciences organizations approach data analysis and accelerate the pace of biomedical innovation.
“Your donation helps us cover global events, ensuring everyone stays informed.”
(Source: EU Start Ups | Tech.EU)
